Clinical Trials Logo

Nausea and Vomiting clinical trials

View clinical trials related to Nausea and Vomiting.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06314906 Recruiting - Nausea and Vomiting Clinical Trials

Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Start date: March 7, 2024
Phase: Phase 3
Study type: Interventional

This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.

NCT ID: NCT06282211 Recruiting - Nausea and Vomiting Clinical Trials

the Efficacy and Safety of Ondansetron Oral Soluble Pellicles

Start date: February 20, 2024
Phase: Phase 3
Study type: Interventional

The name of this prospective study is a multicenter, open-label, randomized controlled clinical study of the efficacy and safety of Ondansetron Oral Soluble Pellicles for the prevention of delayed nausea and vomiting induced by highly emetogenic chemotherapy.

NCT ID: NCT06200168 Recruiting - Nausea and Vomiting Clinical Trials

Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer

Start date: December 20, 2023
Phase: Phase 3
Study type: Interventional

This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.

NCT ID: NCT05690802 Recruiting - Nausea and Vomiting Clinical Trials

The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV

TSEPHCC
Start date: May 16, 2022
Phase: N/A
Study type: Interventional

To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.

NCT ID: NCT05016180 Recruiting - Nausea and Vomiting Clinical Trials

Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery

Start date: September 25, 2020
Phase: Phase 2
Study type: Interventional

Purpose: To explore and compare Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative nausea and vomiting and Early Outcome After Laparoscopic Bariatric Surgery To evaluate and examine TAPB can reduce the application of intraoperative and postoperative opioids and the duration of analgesia

NCT ID: NCT01696734 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Domperidone in Treating Patients With Gastrointestinal Disorders

Start date: October 23, 2012
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.